TrialThe oncologist2026

Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Rachael A Safyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.